These findings suggest that inhibition of Glis2, to an extent achievable by pharmacologic rather than genome level genetic inactivation, can significantly impact the course of ADPKD in an orthologous gene model system. The gene discussed is GLIS2; the disease is autosomal dominant polycystic kidney disease.